Unicycive Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $115.7M
- Price
- $4.16
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.77%
- Volume
- 134.5K
About
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Quick stats
Shares outstanding27.9M
Computed float27.2M
Float / shares97.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001766140
Websitehttps://www.unicycive.com
AI Summary
AI-generated1/50
minorneutrallegal litigation
Recover Investment Losses: Class Action Initiated Against Unicycive Therapeutics, Inc. (UNCY)
Levi & Korsinsky announced a securities class action filed against Unicycive Therapeutics covering investors who purchased UNCY securities between December 29, 2025 and June 29, 2026.
The complaint alleges defendants failed to disclose they had not audited their third-party manufacturing vendor's cGMP compliance, creating risk that FDA approval of OLC would be delayed.
The release itself is law-firm solicitation seeking lead plaintiffs, not new issuer disclosure; treat as low-signal noise.
Red flags
- alleged securities fraud around undisclosed manufacturing-vendor cGMP deficiencies
- class action signals risk of FDA approval delay for OLC